Melanoma-associated antigen D1 (MAGED1) (MAGED1)

Melanoma-associated antigen D1 (MAGED1), also known as NRAGE, is a member of the Type II MAGE family of proteins that acts as a multifunctional adapter protein. Unlike Type I MAGE proteins, which are primarily expressed in tumors, MAGED1 is widely expressed in normal adult tissues, particularly in the brain, where it plays a critical role in neurotrophin signaling by interacting with the p75 neurotrophin receptor (p75NTR). It is heavily involved in regulating apoptosis, cell cycle progression, and the molecular machinery of the circadian clock. In therapeutic contexts, the MAGED1 mRNA transcript is a target of interest for treating mood disorders and depression, as MAGED1 deficiency has been linked to antidepressant-like behavior and altered circadian rhythms in preclinical models. Research suggests that modulating MAGED1 levels can influence the expression of core clock genes and neurotransmitter transporters. While no small molecule drugs directly targeting MAGED1 are currently FDA-approved, experimental approaches using RNA-targeting technologies aim to exploit its role in neuroplasticity and behavioral regulation.

Other names

NRAGEDLXIN-1MAGE-D1Neurotrophin receptor-interacting antigenDlxin1

Targeting the MAGED1 mRNA transcript typically involves RNA interference (siRNA) or antisense oligonucleotides (ASOs) to downregulate protein expression, thereby modulating p75NTR-mediated signaling pathways and circadian clock gene expression.